Biosion, Inc. Appoints Dr. Rakesh Dixit, ADC Thought Leader, to Advisory Board
"I'm delighted to work with the team at Biosion to bolster their mission to deliver breakthrough therapeutics to patients globally."
- "I'm delighted to work with the team at Biosion to bolster their mission to deliver breakthrough therapeutics to patients globally."
- "Biosion's SynTracer internalization platform is uniquely positioned to deliver fit-for-purpose monoclonal antibodies for ADC candidates, a next generation approach to targeting cancer."
- Dr. Dixit was honored in 2020 by the World ADC Forum with its most prestigious award of Long Standing Contributor to ADCs.
- Biosion's lead asset, BSI-045B (anti-TSLP mAb), is currently in phase-II for severe asthma and phase-I for atopic dermatitis.